|Synonyms||(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione|
|Chemical and physical data|
|Molar mass||540.688 g/mol|
|3D model (JSmol)|
|(what is this?)|
Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, and Zetonna for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside the US are ongoing. The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006. Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.
- "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Archived from the original on February 2, 2009. Retrieved 2009-07-30.
- "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.
- Mutch, Elaine; Nave, Ruediger; McCracken, Nigel; Zech, Karl; Williams, Faith M. (2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–64. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.